natgillin/translations-raw huggingface dataset:
Atazanavir hæmmer UGT og kan derfor interferere med irinotecan- metabolismen og medføre øget irinotecan-toksicitet.
Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.
Atazanavir hæmmer UGT og kan interferere med irinotecan- metabolismen og medføre øget irinotecantoksicitet.
Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.
atazanavir og et NNRTI er
Atazanavir (pm):
atazanavir og ombitasvir/
atazanavir and
atazanavir og ritonavir
atazanavir and ritonavir
atazanavir og ritonavir er CYP3A4-
atazanavir and ritonavir is CYP3A4
atazanavir og ritonavir lopinavir/ritonavir
atazanavir and ritonavir lopinavir/ritonavir
atazanavir og ritonavir til
atazanavir and ritonavir to
atazanavir og ritonavir til henholdsvis 400 mg og 200 mg sammen med efavirenz med tæt klinisk monitorering.
respectively, in combination with efavirenz could be considered with close clinical monitoring.
Atazanavir øger
Atazanavir increases
Atazanavir  (historiske kontroller) (hæmning af UGT1A1 og CYP3A-enzymer)
Atazanavir  (historical controls) (inhibition of UGT1A1 and CYP3A enzymes)
Atazanavir  (historiske kontroller) (hæmning af UGT1A1- og CYP3A-enzymer)
Atazanavir  (historical controls) (inhibition of UGT1A1 and CYP3A enzymes)
Atazanavir, doseret 1 time efter
Atazanavir, dosed 1 hr after
Atazanavir, doseret 1 time efter ddI+d4T (fastende)
Atazanavir, dosed 1 hr after ddI+d4T (fasted)
atazanavir, et af indholdsstofferne i
administered with atazanavir, a
Atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, bruges til behandling af HIV- infektioner/AIDS.
Atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, used to treat HIV infections/AIDS.
Atazanavir, samtidig
Atazanavir, simultaneous
Atazanavir, saquinavir (anvendes til behandling af hiv-infektion)
Atazanavir, saquinavir (used to treat HIV infection)
Atazanavir-koncentrationen (når det gives med ritonavir) påvirkes ikke signifikant.
Concentrations of atazanavir were not significantly affected.
Atazanavir-koncentrationen faldt
Atazanavir concentrations were
atazanavir-koncentrationen og
concentrations and is expected to
atazanavir-koncentrationen.
atazanavir concentrations was
Atazanavir-koncentrationer er ikke undersøgt.
Atazanavir concentrations not
Atazanavir-koncentrationer er ikke undersøgt.
Lopinavir/ritonavir concentrations not
Atazanavir/cobicistat (300 mg/150 mg én gang dagligt), tenofoviralafenamid (10 mg)
Atazanavir/cobicistat (300 mg/150 mg once daily), tenofovir alafenamide (10 mg)
Atazanavir/r 300/100 mg:
Atazanavir/ritonavir 300/100 mg QD
Atazanavir/r AUC  0,58 (0,48-0,71)
Atazanavir/r 300/100mg: Atazanavir/r AUC  0.58 (0.48-0.71)
Atazanavir/r Cmax ↓ 0,72 (0,60-0,86)
Atazanavir/r Cmax ↓ 0.72 (0.60-0.86)
Atazanavir/r Cmax ↔ 1,02 (0,85-1,24)
Atazanavir/r Cmax ↔ 1.02 (0.85
Atazanavir/r Cmax  1,02 (0,85–1,24)
Atazanavir/r Cmax  1.02 (0.85
Atazanavir/r Cmax  0,72 (0,60-0,86)
Atazanavir/r Cmax  0.72 (0.60-0.86)
Atazanavir/r Cmin ↓ 0,41 (0,27-0,60)
Atazanavir/r Cmin ↓ 0.41 (0.27-0.60)
Atazanavir/r Cmin  0,28 (0,20-0,40)
Atazanavir/r Cmin  0.28 (0.20-0.40)
Atazanavir/r Cmin  0,41 (0,27-0,60)
Atazanavir/r Cmin  0.41 (0.27-0.60)
Atazanavir/ritonavir
Saquinavir/ritonavir
Atazanavir/Ritonavir (300 mg q.d./100 mg q.d.) + Emtricitabin/ Tenofovirdisoproxilfumarat (200 mg/300 mg q.d.)1
Atazanavir/Ritonavir (300 mg q.d./100 mg q.d.) + Emtricitabine/Tenofovir disoproxil fumarate (200 mg/300 mg q.d.)1
Atazanavir/ritonavir er ikke effektivt over for virale stammer med multiresistensmutationer.
Atazanavir/ritonavir is not effective in viral strains harbouring multiple mutations of resistance.
atazanavir/ritonavir forhøjer
hown to significantly increase
atazanavir/ritonavir kan
atazanavir/ritonavir can be
atazanavir/ritonavir og
atazanavir/ritonavir with
atazanavir/ritonavir og induceres af
atazanavir/ritonavir and induction
atazanavir/ritonavir vil være et fald i
atazanavir/ritonavir is a decrease in
atazanavir/ritonavir, darunavir/ritonavir eller
atazanavir/ritonavir, darunavir/ritonavir, or
atazanavir/ritonavir.
expected to be mitigated by
Atazanavir/Ritonavir/ Tenofovirdisoproxilfumarat (300 mg q.d./100 mg q.d./300 mg q.d.)
Atazanavir/Ritonavir/Tenofovir disoproxil fumarate (300 mg q.d./100 mg q.d./300 mg q.d.)
Atazanavir/ritonavir/efavirenz (400 mg
Atazanavir/ ritonavir/Efavirenz
Atazanavir/ritonavir/efavirenz (400 mg
Atazanavir/ritonavir/Efavirenz
Atazanavir/ritonavir/efavirenz 400 mg
Atazanavir/ritonavir/Efavirenz
Atazanavir/Ritonavir/Rilpivirin
Atazanavir/Ritonavir/Rilpivirine
Atazanavir:
Ritonavir:
Atazanavir: Cmax  24 %* Atazanavir: AUC 22 %* Atazanavir: Cmin*
Atazanavir: Cmax  24%* Atazanavir: AUC  22%* Atazanavir: Cmin
Atazanavir: Cmax  24 %* Atazanavir: AUC 22 %* Atazanavir: Cmin*
Atazanavir: Cmax  24%* Atazanavir: AUC 22%* Atazanavir: Cmin
Atazanavir: sammenligning af atazanavir/ritonavir 300/100 mg x 1 vs atazanavir 300 mg x 1 i kombination med
Atazanavir: comparison of atazanavir/ritonavir 300/100 mg once daily vs. atazanavir 300 mg once daily in combination with darunavir/ritonavir 400/100 mg twice daily.
atazanavirs Cmin kan have
atazanavir Cmin might negatively
atazanavirs Cmin kan have
decrease in atazanavir Cmin might
atazanavirs Cmin kan have negativ
atazanavir Cmin might negatively
atazanavirs Cmin kan have negativ
decrease in atazanavir Cmin might
atazanavirs farmakokinetik.
pharmacokinetics.
atazanavirs og cobicistats CYP3A4-hæmning.
inhibition of CYP3A4 by atazanavir and cobicistat.
ATC kode: A10A C04.
ATC Code: A10A C04.
ATC kode: A10A D04.
ATC Code: A10A D04.
ATC kode: V04D.
ATC code: VO4D
ATC- kode: A10BX11.
ATC code: A10BX11.
ATC- kode: A16AB12.
ATC code: A16AB12.
ATC- kode: L01BA01
ATC code: L01BA01
ATC-kode: A10A B04 Den primære effekt af insulin lispro er regulering af glucosemetabolismen.
ATC code: A10A B04 The primary activity of insulin lispro is the regulation of glucose metabolism.
ATC-kode: A10A E04.
ATC Code: A10A E04.
ATC-kode: A10AE06
ATC code: A10AE06.
ATC-kode: A10BH04.
ATC code: A10BH04.
ATC-kode: A10BX07
ATC code: A10BX07
ATC-kode: A10BX13
ATC code: A10BX13
ATC-kode: B01A B05 Virkningsmekanisme
ATC code: B01A B05 Mechanism of action
ATC-kode: B01AC30.
Heparin, ATC Code: B01AC30.
ATC-kode: C10AX12 Virkningsmekanisme
ATC code: C10AX12 Mechanism of action
ATC-kode: C10AX13 Virkningsmekanisme
ATC code: C10AX13 Mechanism of action
ATC-kode: D06AX13.
ATC code: D06AX13
ATC-kode: J07BA02
ATC code: J07BA02 Mechanism of action
ATC-kode: L01AB01 Virkningsmekanisme
Mechanism of action
ATC-kode: L04AA17 Virkningsmekanisme
ATC code: L04AA17 Mechanism of action
ATC-kode: N05AE05 Virkningsmekanisme
ATC code: N05AE05 Mechanism of action
ATC-kode: N06AX21
ATC code: N06AX21.
ATCkode: A10A B04 Den primære effekt af insulin lispro er regulering af glucosemetabolismen.
ATC code: A10A B04 The primary activity of insulin lispro is the regulation of glucose metabolism.
ATCkode: A10A C04.
ATC Code: A10A C04.
ATCkode: A10A D04.
ATC Code: A10A D04.
ATCvet code: QA10AC1 Insulin (human).
ATCvet code: QA10AC01 Insulin (human).
ATCvet kode: QP53AX27.
ATCvet code: QP53AX27.
ATCvet-kode: Får: QI04AA02
ATCvet code: Sheep: QI04AA02
ATCvet-kode: Q109AB08.
ATC vet code: QI09AB08.
ATCvet-kode: QG03XA91
ATCvet code: QG03XA91.
ATCvet-kode: QI01AD07
ATCvet code: QI01AD07.
ATCvet-kode: QI04AA02 (får) og QI02AA08 (kvæg).
ATCvet codes: QI04AA02 (sheep) and QI02AA08 (cattle).
ATCvet-kode: QI05AA10.
ATCvet code: QI05AA10.
ATCvet-kode: QI06AL01
ATCvet code: QI06AL01.
ATCvet-kode: QI07A
ATCvet code: QI07A
ATCvet-kode: QI07AB01.
ATCvet code: QI07AB01.
ATCvet-kode: QI07AD04.
ATCvet code: QI07AD04.
ATCvet-kode: QI07AD08.
ATCvet code: QI07AD08.
ATCvet-kode: QI07AI02.
ATCvet code: QI07AI02
ATCvet-kode: QI07AI08.
ATCvet code: QI07AI08.
ATCvet-kode: QI07AJ.
ATCvet code: QI07AJ.
ATCvet-kode: QI07AJ06.
ATCvet code: QI07AJ06.
ATCvet-kode: QI07AO
ATC vet code: QI07AO
ATCvet-kode: QI09AB02
ATC vet code: QI09AB02
ATCvet-kode: QJ 01 FA 94.
ATCvet code: QJ01FA94.
ATCvet-kode: QJ01MA 94
ATC vet code: QJ01MA94
ATCvet-kode: QL03AX.
ATCvet code: QL03AX.
ATCvet-kode: QM01AC06
ATCvet code: QMO1AC06.
ATCvet-kode: QM01AC06.
ATCvet: QM01AC06.
ATCvet-kode: QP52AA51
ATCvet code: QP52AA51.
ATCvet-kode: QP52AX60
ATCvet code: QP52AX60
ATCvet-kode: QP53BE02.
ATCvet code: QP53B E02.
ATCvet-kode: QP53BX04.
ATCvet code: QP53BX04.
ATCvet-kode: QP53BX05.
ATCvet code: QP53BX05.
ATCvet-kode: QP54AA54.
ATCvet code: QP54AA54.
ATCvet-kode: QP54AB51.
ATCvet code: QP54AB51.
ATCvet-kode:QM01AC06.
ATCvet code: QM01AC06.
ATCvet. kode: QD07AC.
ATCvet code: QD07AC.
Atelektase
Atelectasis
Atelektase Pleuraeffusion
Pleural effusion
atelektase, faryngealt ødem, pneumonitis
atelectasis, pharyngeal oedema, pneumonitis
Atelektasea
Atelectasisa
Aterosklerose såsom myokardieinfarkt 1, atrioventrikulært blok, trikuspidalklapinsufficiens
Atherosclerosis such as myocardial infarction, atrioventricular block, tricuspid valve incompetence
Aterosklerose såsom myokardieinfarkt 1, atrioventrikulært blok, trikuspidalklapinsufficiens
Atherosclerosis such as myocardial infarction1, atrioventricular block, tricuspid valve incompetence
Aterosklerose såsom myokardieinfarkt 1, atrioventrikulært blok, trikuspidalklapinsufficiens
Hepatic steatosis, hepatomegaly, cholangitis, hyperbilirubinemia
Aterosklerose såsom myokardieinfarkt, atrioventrikulært blok, trikuspidalklapinsufficiens
Atherosclerosis such as myocardial infarction, atrioventricular block, tricuspid valve incompetence
Athen, Attiki 15771 Grækenland
Athens, Attiki 15771 Greece
Athens - GREECE
E-mail: info@virbac.gr
ATIII-mangel, antifosfolipid-syndrom) risikofaktorer, fremskreden alder, patienter med længere tids immobilisering, maligne sygdomme, antikonceptionsmidler og hormonsubstitutionsbehandling (HRT), kirurgi/traume, fedme og rygning.
ATIII deficiency, antiphospholipid syndrome), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking.
ATIII-mangel, antifosfolipid-syndrom), fremskreden alder, patienter med langvarig immobilisering, malignitet, brug af kontraceptiva, hormonbehandling, operation/traume, overvægt eller rygning.
ATIII deficiency, antiphospholipid syndrome), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking.
ATIII-mangel, antifosfolipid-syndrom), risikofaktorer, fremskreden alder, patienter med længere tids immobilisering, maligne sygdomme, antikonceptionsmidler og hormonsubstitutionsbehandling (HRT), kirurgi/traume, fedme og rygning.
ATIII deficiency, antiphospholipid syndrome), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking.
atipamexolhydrochlorid, anvendes ved en dosis på 0,2 mg/kg legemsvægt ved intramuskulær injektion for at fjerne disse bivirkninger.
If symptoms are severe or persist the alpha-2-adreno-receptor antagonist atipamezole hydrochloride may be used at a dose of 0.2 mg/kg bodyweight by intramuscular injection to reverse these side-effects.
Atipamezol bør ikke gives de første 30 minutter efter administration af ketamin.
Atipamezole should not be administered prior to 30 minutes following ketamine administration.
Atipamezol bør ikke gives før 30 minutter efter administration af ketamin
Atipamezole should not be administered prior to 30 minutes following ketamine administration.
Atopisk dermatitis er en overreaktion af hudens immunsystem, der fremkalder en betændelsestilstand (kløe, rødt udslæt og tør hud).
In atopic dermatitis, an over-reaction of the skin’s immune system causes skin inflammation (itchiness, redness and dryness).
Atopisk dermatitis er en overreaktion af hudens immunsystem, der fremkalder en betændelsestilstand (kløe, rødt udslæt, tør hud).
In atopic dermatitis, an over-reaction of the skin’s immune system causes skin inflammation (itchiness, redness, dryness).
Atorvastatin
Hepatic impairment
Atorvastatin (40 mg en gang dagligt)/rilpivirin1
Atorvastatin (40 mg once daily)/ Rilpivirine1
Atorvastatin (40 mg én gang dagligt)/Rilpivirin1
Atorvastatin (40 mg once daily)/ Rilpivirine1
atorvastatin (kolesterolsænkende medicin) salmeterol (medicin mod astma – vedligeholdelsesbehandling, forebyggende mod astmalignende anfald ved kronisk obstruktiv lungesygdom (KOL)
atorvastatin (used to lower blood cholesterol) salmeterol (used to achieve long-term asthma control, bronchospasm prevention with COPD)
Atorvastatin - Samtidig administration af atorvastatin og ticagrelor øgede atorvastatinsyrens Cmax med 23 % og AUC med 36 %.
Atorvastatin - Co-administration of atorvastatin and ticagrelor increased atorvastatin acid Cmax by 23% and AUC by 36%.
Atorvastatin - Samtidig administration af atorvastatin og ticagrelor øgede atorvastatinsyrens Cmax med 23 % og AUC med 36 %.
Atorvastatin – Co-administration of atorvastatin and ticagrelor increased atorvastatin acid Cmax by 23% and AUC by 36%.
Atorvastatin 10 mg 1 gang daglig (Nelfinavir 1250 mg 2 gange daglig)
Atorvastatin 10 mg qd (Nelfinavir 1250 mg bid)
Atorvastatin 10 mg x 1
10 mg once daily
Atorvastatin 10 mg x 1
Atorvastatin 10 mg QD
atorvastatin AUC 2,12 (1,72-2,62)  atorvastatin Cmax 1,70 (1,42-2,04)  atorvastatin Cmin ikke undersøgt
atorvastatin Cmax 1.70 (1.42-2.04) ↑
atorvastatin AUC ↑ 3-4 gange atorvastatin Cmin ↑ ≈5,5-10 gange atorvastatin Cmax ↑ ≈2 gange
atorvastatin AUC ↑ 3-4 fold atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin Cmax ↑ ≈2 fold
Atorvastatin AUC ↑ 74 % Nelfinavir AUC koncentrationer er ikke målt
Atorvastatin AUC ↑ 74 % Nelfinavir AUC concentrations not measured
Atorvastatin AUC ↑ 74 % Nelfinavir AUC koncentrationer er ikke målt
Ethinyl estradiol AUC ↓47% Nelfinavir concentrations not measured
atorvastatin AUC ↔ atorvastatin Cmin ↓ 15 % atorvastatin Cmax ↑ 35 % rilpivirin AUC ↔ rilpivirin Cmin ↔ rilpivirin Cmax ↓ 9 %
atorvastatin AUC ↔ atorvastatin Cmin ↓ 15% atorvastatin Cmax ↑ 35% rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↓ 9
Atorvastatin Cmax ↑ 8,6 gange Atorvastatin AUC ↑ 9,4 gange Atorvastatin Cmin ↑ 5,2 gange
Atorvastatin Cmax ↑ 8.6 fold Atorvastatin AUC ↑ 9.4 fold Atorvastatin Cmin ↑ 5.2 fold
atorvastatin doser på mere end 20 mg om dagen (mod forhøjet kolesterol i blodet) fluticasonpropionat og lignende medicin mod astma, medmindre dette skønnes nødvendigt.
doses of atorvastatin greater than 20 mg per day (used to lower cholesterol) fluticasone propionate and similar medicines used to treat asthma, unless considered essential.
Atorvastatin eller andre statiner (til nedsættelse af kolesterol i blodet)
Atorvastatin or other statins (for lowering blood cholesterol)
Atorvastatin eller andre statiner (til nedsættelse af kolesterol i blodet)
Atorvastatinor other statins(for lowering blood cholesterol)
Atorvastatin eller rosuvastatin (mod for højt kolesteroltal), da Norvir kan øge niveauerne af disse lægemidler i blodet.
Atorvastatin or rosuvastatin (for high cholesterol) as Norvir may raise the blood levels of these medicines.
Atorvastatin er mindre afhængig af CYP3A4 mht. metabolisme end lovastatin eller simvastatin
Atorvastatin is less dependent on CYP3A4 for metabolism than lovastatin or simvastatin
Atorvastatin og andre statiner (CYP3A4-substrater, fx simvastatin, lovastatin, rosuvastatin) (CYP3A4/5- og/eller BCRP- substrater))
Atorvastatin and other statins (CYP3A4 substrates e.g., simvastatin, lovastatin, rosuvastatin) (CYP3A4/5 and/or BCRP substrates))
atorvastatin op til 20 mg om dagen (mod forhøjet kolesterol i blodet)
atorvastatin up to 20 mg per day (used to lower cholesterol)
atorvastatin*
HMG-CoA REDUCTASE INHIBITORS
atorvastatin, fluvastatin,
pitavastatin or pravastatin.
Atorvastatin, fluvastatin, lovastatin, rosuvastatin, simvastatin (kolesterolsænkende medicin).
atorvastatin, fluvastatin, lovastatin, rosuvastatin, simvastatin (cholesterol-lowering medicines)
atorvastatin, fluvastatin, pitavastin, pravastatin og rosuvastatin, lægemidler, der anvendes til at sænke kolesterol
atorvastatin, fluvastatin, pitavastatin, pravastatin and rosuvastatin, medicines used to lower cholesterol
atorvastatin, lovastatin, simvastatin, lægemidler, der anvendes til at sænke kolesterolniveauet
atorvastatin, lovastatin, simvastatin, medicines used to lower cholesterol
atorvastatin, pravastatin og fluvastatin (anvendes til at sænke mængden af kolesterol i blodet)
atorvastatin, pravastatin, and fluvastatin (used to lower blood cholesterol)
atorvastatin, pravastatin, fluvastatin, pitavastatin og rosuvastatin (bruges til at sænke kolesterolindholdet i blodet)
atorvastatin, pravastatin, fluvastatin, pitavastatin and rosuvastatin (used to lower blood cholesterol)
atorvastatin, rosuvastatin, pravastatin, fluvastatin – anvendes til at sænke kolesteroltallet
atorvastatin, rosuvastatin, pravastatin, fluvastatin - used to lower cholesterol
Atorvastatin-dosis må ikke overstige
The dose of atorvastatin should not
Atorvastatin/ tenofovirdisoproxilfumarat
Atorvastatin/Tenofovir disoproxil fumarate
Atorvastatin/efavirenz (10 mg én gang dagligt/600 mg én gang dagligt)
Atorvastatin/Efavirenz (10 mg once daily/600 mg once daily)
Atorvastatin/Emtricitabin
Atorvastatin/Emtricitabine
Atorvastatin: AUC: ↑ 5,9-gange Cmax: ↑ 4,7-gange
Atorvastatin: AUC: ↑ 5.9-fold Cmax: ↑ 4.7-fold
Atorvastatin: Cmax  184 % Atorvastatin: AUC  153 % Atorvastatin: Cmin  73 %
Atorvastatin: Cmax  184% Atorvastatin: AUC  153
Atorvastatin: Cmax  184 % Atorvastatin: AUC  153 % Atorvastatin: Cmin  73 %
Atorvastatin: Cmax  184% Atorvastatin: AUC  153% Atorvastatin: Cmin  73
Atorvastatin: Ranexa 1000 mg to gange dagligt øgede Cmax og AUC for atorvastatin 80 mg en gang dagligt med henholdsvis faktor 1,4 og 1,3 og ændre Cmax og AUC for atorvastatins metabolitter med mindre end 35 %.
Atorvastatin: Ranexa 1000 mg twice daily increased Cmax and AUC of atorvastatin 80 mg once daily by 1.4- and 1.3 -fold, respectively and changed the Cmax and AUC of atorvastatin metabolites less than 35%.
atorvastatindoser på mere end 20 mg om dagen (mod forhøjet kolesterol i blodet) fluticasonpropionat og lignende medicin mod astma, medmindre dette skønnes nødvendigt.
doses of atorvastatin greater than 20 mg per day (used to lower cholesterol) fluticasone propionate and similar medicines used to treat asthma, unless considered essential.
atorvastatindosis på basis af
adjustments, however, the
Atorvastatins Cmax blev reduceret med 38 %, og medianværdien for tmax blev forsinket fra 1 time til 3 timer med liraglutid.
Atorvastatin Cmax was decreased by 38% and median tmax was delayed from 1 h to 3 h with liraglutide.
Atorvastin anbefales ikke samtidig med Aptivus plus lavdosis ritonavir.
Co-administration of atorvastatin and Aptivus, co-administered with low dose ritonavir, is not recommended.
atorvastin, som bruges til at nedsætte kolesterolniveauet
atorvastatin, used to reduce cholesterol levels
Atosiban 6,75 mg/0,9 ml, injektionsvæske, opløsning skal anvendes med det samme.
The atosiban 6.75 mg/0.9 ml, solution for injection should be used immediately.
Atosiban er indiceret til at udsætte truende for tidlig fødsel hos voksne gravide kvinder med:
Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with:
Atosiban SUN 37,5 mg/5 ml koncentrat til infusionsvæske, opløsning
Atosiban SUN 37.5 mg/5 ml concentrate for solution for infusion
Atosiban SUN 37,5 mg/5 ml koncentrat til infusionsvæske, opløsning er en klar, farveløs opløsning uden partikler.
Atosiban SUN 37.5 mg/5 ml concentrate for solution for infusion is a clear, colourless solution without particles.
Atosiban SUN 37,5 mg/5 ml koncentrat, sterilt atosiban
Atosiban SUN 37.5 mg/5 ml sterile concentrate atosiban
Atosiban SUN 6,75 mg/0,9 ml injektionsvæske atosiban
Atosiban SUN 6.75 mg/0.9 ml injection atosiban
Atosiban SUN 6,75 mg/0,9 ml injektionsvæske er en klar, farveløs opløsning uden partikler.
Atosiban SUN 6.75 mg/0.9 ml solution for injection is a clear, colourless solution without particles.
Atosiban SUN 6,75 mg/0,9 ml injektionsvæske, opløsning
Atosiban SUN 6.75 mg/0.9 ml solution for injection
Atosiban SUN er et "generisk lægemiddel".
Atosiban SUN is a ‘generic medicine’.
Atosiban SUN er ikke undersøgt hos gravide kvinder under 18 år.
Atosiban SUN has not been studied in pregnant women less than 18 years old.
Atosiban SUN gives i en vene (intravenøst) i tre trin:
Atosiban SUN will be given into a vein (intravenously) in three stages:
Atosiban SUN gives intravenøst i tre successive stadier:
Atosiban SUN is given intravenously in three successive stages:
Atosiban SUN indeholder atosiban (INN), et syntetisk peptid ([Mpa1, D-Tyr(Et)2, Thr4,Orn8]- oxytocin), der er en kompetitiv antagonist til humant oxytocin på receptorniveau.
Atosiban SUN contains atosiban (INN), a synthetic peptide ([Mpa1, D-Tyr(Et)2, Thr4,Orn8]-oxytocin) which is a competitive antagonist of human oxytocin at receptor level.
Atosiban SUN indeholder atosiban.
Atosiban SUN contains atosiban.
Atovaquon / abacavir
Atovaquone/Abacavir
Atovaquon / zidovudin (750 mg 2 gange daglig med mad / 200 mg 3 gange
Atovaquone/Zidovudine (750 mg twice daily with food/200 mg thrice daily)
Atovaquon og proguanil
Atovaquone and proguanil
Atovaquon og proguanilhydrochlorid/ tenofovirdisoproxilfumarat
Atovaquone and proguanil hydrochloride/Tenofovir disoproxil fumarate
Atovaquon Ritonavir doseret som en farmakokinetisk forstærker eller som et antiretroviralt stof fremkalder glukuronidation og forventes som følge heraf at nedsætte plasmakoncentrationerne af atovaquon.
Atovaquone Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces glucuronidation and as a result is expected to decrease the plasma concentrations of atovaquone.
atovaquon, der er et lægemiddel, som anvendes til behandling af en specifik type lungebetændelse og malaria;
atovaquone, a medicine used to treat a certain type of pneumonia and malaria;
atovaquon, der er et lægemiddel, som anvendes til behandling af en særlig type lungebetændelse og malaria;
atovaquone, a medicine used to treat a certain type of pneumonia and malaria;
atovaquon/proguanil og
and artemether/lumefantrine
atovaquon/proguanil og
atovaquone/proguanil with
Atovaquon:
Diltiazem:
ATP -kohorte(1)
ATP cohort(1)
ATP-kohorte(1)
ATP(1)
Atriance 5 mg/ml infusionsvæske, opløsning.
Atriance 5 mg/ml solution for infusion Nelarabine
Atriance anvendes til behandling af patienter med akut lymfoblastisk T-celle leukæmi (T-ALL) eller lymfoblastisk T-celle lymfom (T-LBL).
Atriance is used to treat patients with T-cell acute lymphoblastic leukaemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL).
Atriance anvendes, når mindst to typer kemoterapi har været uden virkning eller ikke længere virker.
Atriance is used when the cancer has not to responded to, or has stopped responding to, at least two types of chemotherapy.
Atriance blev anvendt i to hovedundersøgelser af patienter med T-ALL og T-LBL, hos hvem en eller flere typer kræftbehandling var holdt op med at virke.
Atriance has been studied in two main studies of patients with T-ALL and T-LBL whose cancer had stopped responding to one or more previous cancer treatments.
Atriance er et kræftlægemiddel, der indeholder det aktive stof nelarabin.
Atriance is a cancer medicine that contains the active substance nelarabine.
Atriance er godkendt under "særlige omstændigheder".
Atriance has been authorised under ‘exceptional circumstances’.
Atriance findes i pakninger med 6 hætteglas.
Atriance is supplied in packs of 6 vials.
Atriance gives ved drop i en vene under opsyn af en læge med erfaring i anvendelse af denne type lægemidler.
Atriance is given by drip into a vein under the supervision of a doctor who has experience in the use of these types of medicine.
Atriance infusionsvæske er en klar, farveløs opløsning.
Atriance solution for infusion is a clear, colourless solution.
Atriance virkede hos en del af patienterne i begge undersøgelser.
Atriance was shown to be effective in a proportion of the patients in both studies.
atriefibrillation
atrial fibrillation
Atriefibrillering; takykardi; bradykardi^; palpitationer
Atrial fibrillation; Tachycardia; Bradycardia^; Palpitations
Atrieflagren
Atrial Flutter